Cox and Abbadi outline next steps for BDNF/TrkB-targeted therapy, including translating the approach to high-grade serous ovarian cancer.
Jumana Abbadi, MD
Advertisement
Articles by Jumana Abbadi, MD
Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative breast tumors, a potential drug target.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
5